Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1123846

	registered interest
	date	30/04/2019
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Carbon Emissions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent discussions he has had with his counterparts in (a) the US, (b) China and (c) Russia on reducing their cumulative CO2 emissions.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	249308
	answer	answer is ministerial correction date of answer 07/05/2019 answer text <p>The UK continues to demonstrate the strong leadership needed to tackle climate change, both at home and abroad. As an issue of significant public and international importance, my rt. hon. Friend the Secretary of State and I regularly meet with their international counterparts to discuss a range of issues including climate change. As the Cabinet Minister most directly responsible for climate change, I regularly attend major international climate meetings, recently at COP24 in Poland.</p> answering member constituency Devizes answering member printed Claire Perry question first answered 07/05/2019 16:04:35 answering member 3974 label Biography information for Claire Perry
	tabling member	4264 label Biography information for Stephen Doughty

1147816

	registered interest
	date	02/10/2019
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Business
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what impact analysis her Department prepared (a) from 1 January 2018 to 23 July 2019 and (b) since 23 July 2019 as a result of discussions at EU XTP and EU XTPO committees on business supply chains as part of preparations for Operation Kingfisher, and if she will place copies of those analyses in the Library.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	293595
	answer	answer is ministerial correction date of answer // answer text <p>Department for Business, Energy and Industrial Strategy indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered // answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1190706

	registered interest
	date	27/04/2020
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Iron and Steel: Recycling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is taking to support the steel recycling sector during the covid-19 outbreak.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	40628
	answer	answer is ministerial correction date of answer 05/05/2020 answer text <p>The Department has been in close contact with the metals recycling sector during this challenging period. The sector has seen a reduction to material flows throughout the economy, which is impacting their output.</p><p>The metals recycling sector has made use of the Coronavirus Job Retention Scheme and we have also promoted the Coronavirus Business Interruption Loan Scheme, alongside other business support schemes.</p><p>The Government is mindful of the important role that the metals recycling sector plays in keeping our economy moving and we continue to be receptive to their concerns.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 05/05/2020 09:11:36 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1276760

	registered interest
	date	14/01/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Vaccination: Manufacturing Industries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, how many vaccine manufacturing facilities (a) for the production of raw materials, active ingredients, coupling and formulation and (b) for fill and finish there are in the UK; and how many of those facilities are being used for covid-19 vaccine production.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	137941
	answer	answer is ministerial correction date of answer 19/01/2021 answer text <p>We have been monitoring the requirements across the supply chain from supplier through to patients for some time. All vaccine candidates’ supply and onward deployment have clear supply chain plans across the value chain, including materials, manufacturing, transportation, storage, and distribution. <br> <br> Three of the UK's seven COVID-19 vaccines are being manufactured in the UK. The Government has worked closely with the manufacturers to ensure that we have sufficient capacity secured.</p><p>The Government has also invested over £300 million in securing and scaling up the UK’s manufacturing capabilities to be able to respond to this pandemic.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 137942 question first answered 19/01/2021 17:29:58 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1276762

	registered interest
	date	14/01/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Vaccination: Manufacturing Industries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, how many bio-reactors used in vaccine production there are in the UK; and how many of those bio-reactors are being used for covid-19 vaccine production.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	137942
	answer	answer is ministerial correction date of answer 19/01/2021 answer text <p>We have been monitoring the requirements across the supply chain from supplier through to patients for some time. All vaccine candidates’ supply and onward deployment have clear supply chain plans across the value chain, including materials, manufacturing, transportation, storage, and distribution. <br> <br> Three of the UK's seven COVID-19 vaccines are being manufactured in the UK. The Government has worked closely with the manufacturers to ensure that we have sufficient capacity secured.</p><p>The Government has also invested over £300 million in securing and scaling up the UK’s manufacturing capabilities to be able to respond to this pandemic.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 137941 question first answered 19/01/2021 17:29:58 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1277461

	registered interest
	date	18/01/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether the decision by Pfizer to make changes to manufacturing processes of its covid-19 vaccine to boost production will affect the distribution of that vaccine to the UK from late January to early February 2021.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	139002
	answer	answer is ministerial correction date of answer 21/01/2021 answer text <p>Vaccines are a precious resource and are in very high demand across the world; therefore, for security reasons it is not possible to provide detail about the size of our supplies or give exact detail about future deliveries.</p><p> </p><p>We have been monitoring the requirements across the supply chain from supplier through to patients for some time. All vaccine candidates’ supply and onward deployment have clear supply chain plans across the value chain, including materials, manufacturing, transportation, storage, and distribution.</p><p> </p><p>As of 18 January 2021, over 4.6 million people in the UK had been vaccinated with the first dose of the vaccine. We are in the process of understanding the implications of Pfizer’s announcement on 15 January regarding upgrades to its manufacturing capacity. We continue to work to meet our target of vaccinating all four priority groups, as advised by the Joint Committee on Vaccination and Immunisation, by the middle of February.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 21/01/2021 16:21:01 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1279278

	registered interest
	date	21/01/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answers of 19 January 2021 to Questions 137942 and 137941, if he will provide a breakdown of the £300 million invested in securing and scaling up UK manufacturing capacity by (a) type of capacity, (b) geographical location and (c) the date that investment was delivered.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	141474
	answer	answer is ministerial correction date of answer 26/01/2021 answer text <p>The Government invested over £300 million in 2020 to secure and scale-up the UK’s manufacturing capabilities to respond to this pandemic, including:</p><p>- £127 million towards the Cell and Gene Therapy Catapult Braintree in Essex;</p><p>- £93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire;</p><p>- £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;</p><p>- £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire; and</p><p>- £65.5 million for the manufacture of the University of Oxford / AstraZeneca vaccine.</p><p> </p><p>In addition to the above, we have also funded the fill and finish of vaccines through a contract with Wockhardt in Wrexham, North Wales, as well as the expansion of the Valneva factory in Livingston, Scotland. However, we are not able to give further details on these two developments owing to commercial confidentiality.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/01/2021 16:15:42 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1279279

	registered interest
	date	21/01/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to secure UK covid-19 vaccine manufacturing capacity and protect those manufacturing establishments from flood, fire, malfunction and other security threats.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	141475
	answer	answer is ministerial correction date of answer 26/01/2021 answer text <p>The Government takes security extremely seriously and is ensuring all necessary steps are taken.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/01/2021 16:08:01 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1279579

	registered interest
	date	22/01/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, how many doses of the (a) Pfizer-BioNTech and (b) Oxford-AstraZeneca vaccine are physically present in the UK and being held in storage, yet to be deployed or prepared for delivery.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	141990
	answer	answer is ministerial correction date of answer 27/01/2021 answer text <p>The Government has procured 40 million doses of the Pfizer/BioNTech and 100 million doses of the Oxford University/AstraZeneca vaccines.</p><p> </p><p>The UK was the first country in the world to start a vaccination programme using these vaccines. As of 26 January 2021, over 6.85 million people across the UK have been vaccinated with the first dose of the vaccine. We continue to work to meet our target of vaccinating all four priority groups by 15 February.</p><p> </p><p>Vaccines are a precious resource in very high demand across the world; therefore, for security reasons it is not possible to provide detail about the size of our supplies and exact detail about deliveries.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 27/01/2021 17:19:30 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty

1279593

	registered interest
	date	22/01/2021
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, how many UK based manufacturing facilities are capable of re-engineering and manufacturing (a) mRNA, (b) viral vector, (c) whole virus and (d) protein subunit vaccines to address emerging variants of the covid-19 virus.
	tabling member constituency	Cardiff South and Penarth
	tabling member printed	Stephen Doughty
	uin	141992
	answer	answer is ministerial correction date of answer 27/01/2021 answer text <p>The Government has made several strategic investments in UK vaccine manufacturing capabilities to increase its capacity, ensuring we are able to manufacture across different vaccine technologies and embed resilience. This includes:</p><p> </p><ul><li>The acceleration and expansion of flexible vaccine manufacturing capabilities at the UK’s first Vaccine Manufacturing and Innovation Centre (VMIC) in Harwell.</li><li>Collaborating with the Cell and Gene Therapy Catapult to fund a state-of-the-art Manufacturing Innovation Centre in Braintree.</li><li>Expansion of the Valneva factory in Livingston, Scotland, which is capable of whole virus manufacture.</li></ul><p> </p><p>Both the VMIC and Braintree sites are flexible to vaccine types, including messenger RNA (mRNA), viral vector, and protein sub-unit. These sites could have a role in providing capability to manufacture vaccines to address the emerging variants of the COVID-19 virus.</p><p> </p><p>The Government has also invested through UK Research and Innovation (UKRI) to support the creation of a new Centre of Excellence in mRNA vaccine manufacture at the Centre for Process Innovation (CPI), with equipment that can manufacture mRNA for vaccines. This funding has upgraded CPI’s National Biologics Manufacturing Centre at Darlington to obtain good manufacturing practice certification for the manufacture of RNA products including mRNA for clinical trials. A key advantage of RNA vaccines is how quickly they can be developed compared with other platforms.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 27/01/2021 17:18:03 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4264 label Biography information for Stephen Doughty